✦ LIBER ✦

Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands

✍ Scribed by Frank G.A Jansman; Maarten J Postma; David van Hartskamp; Pax H.B Willemse; Jacobus R.B.J Brouwers

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN10 COST ANALYSIS OF CAPECITABINE VERS

✍ MJ Postma; D van Hartskamp; FG Jansman; PH Willemse; JR Brouwers 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PCN46 COST-MINIMIZATION ANALYSIS OF CAPE

✍ MG Saggia; VD Nasciben; EA Santos; S Stefani 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PCN113 PHARMACOECONOMIC ANALYSIS OF CAPE

✍ HH Chen; CS Chang; LT Chen; WT Chen; TC Hsu; JY Wang; CY Wen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Pharmacoeconomic Analysis of Capecitabin

✍ Tzu-Chi Hsu; Hong-Hwa Chen; Ming-Chin Yang; Hwei-Ming Wang; Jye-Hann Chuang; Shu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB

5-Fluorouracil or capecitabine in the tr

✍ Fausto Petrelli, Mary Cabiddu, Sandro Barni 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 492 KB

PCN106 Capecitabine Plus Oxaliplatin (CA

✍ van Gils, C.W.M.; de Groot, S.; Redekop, W.K.; Uyl-De Groot, C.A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB